Kodiak Sciences (KOD) has received a new Buy rating, initiated by Jefferies analyst, Maury Raycroft.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Maury Raycroft has given his Buy rating due to a combination of factors related to Kodiak Sciences’ promising drug pipeline and financial position. The company has three drugs in phase III trials for eye diseases, with significant data readouts expected in 2026. The lead asset, KSI-101, has shown encouraging phase I results in treating macular edema secondary to inflammation, outperforming a key competitor’s drug in early trials.
Additionally, Kodiak Sciences has a strong financial runway with $104 million in cash, supporting operations into 2026. The company’s second asset, Tarcocimab, is undergoing phase III trials and has shown mixed results, but upcoming data could provide further clarity. The potential market opportunity for KSI-101 is substantial, and the anticipated data readouts from competitors could act as catalysts for stock movement, contributing to the optimistic outlook and Buy rating.
According to TipRanks, Raycroft is a 4-star analyst with an average return of 9.1% and a 41.37% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Cardiff Oncology, and Travere Therapeutics.